MX2017008904A - Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica. - Google Patents

Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica.

Info

Publication number
MX2017008904A
MX2017008904A MX2017008904A MX2017008904A MX2017008904A MX 2017008904 A MX2017008904 A MX 2017008904A MX 2017008904 A MX2017008904 A MX 2017008904A MX 2017008904 A MX2017008904 A MX 2017008904A MX 2017008904 A MX2017008904 A MX 2017008904A
Authority
MX
Mexico
Prior art keywords
artery disease
coronary artery
blood based
atherosclerotic coronary
based biomarkers
Prior art date
Application number
MX2017008904A
Other languages
English (en)
Inventor
Voros Szilard
O Brown Bradley
B Marvasty Idean
Original Assignee
Global Genomics Group Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Genomics Group Llc filed Critical Global Genomics Group Llc
Publication of MX2017008904A publication Critical patent/MX2017008904A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ecology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La invención, en algunos aspectos, se relaciona con métodos para evaluar a un sujeto humano para determinar si presenta enfermedad de arteria coronaria ateroesclerótica (ASCAD) o si tiene una placa ateroesclerótica coronaria. En algunos aspectos, la invención se relaciona con métodos y kits útiles para diagnosticar, clasificar, caracterizar y tratar CAD ateroesclerótica y/o una placa ateroesclerótica coronaria.
MX2017008904A 2015-01-09 2016-01-08 Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica. MX2017008904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101445P 2015-01-09 2015-01-09
PCT/US2016/012725 WO2016112337A1 (en) 2015-01-09 2016-01-08 Blood based biomarkers for diagnosing atherosclerotic coronary artery disease

Publications (1)

Publication Number Publication Date
MX2017008904A true MX2017008904A (es) 2018-02-09

Family

ID=56356500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008904A MX2017008904A (es) 2015-01-09 2016-01-08 Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica.

Country Status (12)

Country Link
US (2) US10254272B2 (es)
EP (3) EP3650852B1 (es)
KR (1) KR20170102983A (es)
CN (2) CN107427221B (es)
CA (1) CA2973116C (es)
HU (2) HUE047951T2 (es)
IL (1) IL253179A0 (es)
MX (1) MX2017008904A (es)
SG (1) SG11201705444QA (es)
TW (2) TWI610079B (es)
WO (1) WO2016112337A1 (es)
ZA (1) ZA201705032B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047951T2 (hu) * 2015-01-09 2020-05-28 Global Genomics Group Llc Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN107491656B (zh) * 2017-09-04 2020-01-14 北京航空航天大学 一种基于相对危险度决策树模型的妊娠结局影响因子评估方法
US11513131B2 (en) * 2018-01-22 2022-11-29 Global Genomics Group, LLC Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
WO2019173709A1 (en) * 2018-03-09 2019-09-12 Nearing Bruce D High throughput ecg heterogeneity assessment to determine presence of coronary artery stenosis
US20210088522A1 (en) * 2018-03-29 2021-03-25 Keio University Marker for determining sensitivity of irinotecan-containing anti-cancer agent therapy
US11036779B2 (en) * 2018-04-23 2021-06-15 Verso Biosciences, Inc. Data analytics systems and methods
CN109164183A (zh) * 2018-09-29 2019-01-08 中国检验检疫科学研究院 肝脏损伤相关差异性内源性标志物及其筛选方法和应用
CN110487922B (zh) * 2018-12-17 2022-09-27 广西中烟工业有限责任公司 一种烟叶中苏糖酸和苏糖酸酯的gc-ms分析方法
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
KR102177280B1 (ko) * 2019-05-09 2020-11-10 고려대학교 세종산학협력단 호모시스테인 설핀산 또는 시스테인산을 포함하는 급성심근경색 진단용 바이오마커 조성물
CN111505131B (zh) * 2020-01-02 2023-03-31 东莞东华医院有限公司 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型
CN111983160B (zh) * 2020-08-14 2022-08-09 中元伯瑞生物科技(珠海横琴)有限公司 神经酸在治疗脑卒中药物中的应用
US20240079145A1 (en) * 2021-01-15 2024-03-07 My Lua Llc Systems and methods for deriving health indicators from user-generated content
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法
CN114324641A (zh) * 2021-12-22 2022-04-12 山东英盛生物技术有限公司 一种冠心病代谢标志物及在诊断、预后方面的应用
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
CN114705782B (zh) * 2022-04-07 2023-12-01 中国人民解放军总医院第一医学中心 用于诊断或监测结直肠癌的血浆代谢标志物组合及应用
CN117110627B (zh) * 2023-10-18 2024-01-09 天津云检医学检验所有限公司 用于新生儿干血斑先天性心脏病及其亚型评估的标志物
CN117405870B (zh) * 2023-12-15 2024-03-19 北京市心肺血管疾病研究所 基于血清脂质代谢物构建冠心病患者不稳定斑块表型的预测模型
CN118010893A (zh) * 2024-04-09 2024-05-10 北京市心肺血管疾病研究所 类花生酸在用于评估急性冠脉综合征患者血运重建术后发生不良心血管事件风险中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE458199T1 (de) * 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
BRPI0416639A (pt) * 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
EP2140271A2 (en) 2007-03-26 2010-01-06 BG Medicine, Inc. Methods for detecting coronary artery disease
CA2692457A1 (en) * 2007-07-03 2009-01-08 Joslin Diabetes Center, Inc. Treatment of cardiovascular disease with salicylates
EP2164977B1 (en) * 2007-07-17 2013-10-30 Metabolon, Inc. Biomarkers for pre-diabetes and methods using the same
BR112012002333A2 (pt) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
WO2011063470A1 (en) * 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
KR20130056855A (ko) * 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
DK2385374T4 (en) 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
CA2805794A1 (en) * 2010-07-19 2012-01-26 Otago Innovation Limited Signal biomarkers
WO2013052965A2 (en) * 2011-10-06 2013-04-11 Miragen Therapeutics Control of whole body energy homeostasis by microrna regulation
EP2965092A1 (en) * 2013-03-08 2016-01-13 Zora Biosciences OY Non-high density lipoprotein derived cvd markers
AU2014265669B2 (en) * 2013-05-14 2020-05-14 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
CA2945165A1 (en) * 2014-04-08 2015-10-15 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
WO2016073547A1 (en) * 2014-11-05 2016-05-12 Metabolon, Inc. System, method and apparatus for determining the effect of genetic variants
HUE047951T2 (hu) * 2015-01-09 2020-05-28 Global Genomics Group Llc Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására

Also Published As

Publication number Publication date
US20190391131A1 (en) 2019-12-26
TWI610079B (zh) 2018-01-01
KR20170102983A (ko) 2017-09-12
EP3650852A1 (en) 2020-05-13
EP3242588A1 (en) 2017-11-15
US20160202239A1 (en) 2016-07-14
CA2973116C (en) 2023-08-15
TW201802471A (zh) 2018-01-16
US10254272B2 (en) 2019-04-09
HUE056203T2 (hu) 2022-01-28
TWI690707B (zh) 2020-04-11
EP3967217A1 (en) 2022-03-16
CN113156096A (zh) 2021-07-23
CN107427221B (zh) 2021-03-09
EP3242588A4 (en) 2018-10-17
ZA201705032B (en) 2019-09-25
EP3650852B1 (en) 2021-08-18
IL253179A0 (en) 2017-08-31
EP3242588B1 (en) 2019-10-16
HUE047951T2 (hu) 2020-05-28
TW201725387A (zh) 2017-07-16
SG11201705444QA (en) 2017-07-28
CA2973116A1 (en) 2016-07-14
CN107427221A (zh) 2017-12-01
WO2016112337A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
MX2017008904A (es) Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica.
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
WO2016184935A3 (en) Method for evaluating manual dexterity
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
CR10087A (es) Dispositivo y procedimientos para detección de micotoxinas.
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
AR110378A1 (es) Métodos para determinar el estado del cáncer colorrectal en una persona
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
MX2018001831A (es) Biomarcadores para el tratamiento de alopecia areata.
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
GB2552271A (en) A method for diagnosing lung cancer
MX2015015015A (es) Metodo para diagnosticar cancer.
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
WO2016100745A3 (en) Methods and compositions related to transplant-associated thrombotic microangiopathy
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
WO2016100549A3 (en) Ceramides for evaluating risk of cardiovascular disease